Back

Serum uric acid, influence of sacubitril/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF

30 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Novel Pharmacotherapies and Surgical Procedures for Heart Failure: How To Succeed? Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Senthil Selvaraj

Duke University School of Medicine, Durham (United States of America)

6 More presentations in this session

Presentation thumbnail
Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial
Doctor A. Sarraju (Stanford, US)
Abstract Slides Video
Presentation thumbnail
The renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure (RECEDE-CHF) trial
Doctor N. Mordi (Dundee, GB)
Abstract Slides Video
Presentation thumbnail
Restricted mean survival time analysis in heart failure clinical trials
Doctor C. Perego (Cinisello Balsamo, IT)
Abstract Slides Video
Presentation thumbnail
Hybrid transcatheter and minimally invasive left ventricular reconstruction for the treatment of ischemic cardiomyopathy: mid-term results
Doctor P. Klein (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
LIVE procedure for ischemic heart failure: the evolution of an unique technique
Doctor P. Neves (Vila Nova de Gaia, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Novel Pharmacotherapies and Surgical Procedures for Heart Failure: How To Succeed?

The Event

Event poster

ESC Congress 2020

30 August 2020 08:30 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Session
Navigating through heart failure device therapies
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice